Skip to main content

Table 6 Generalized estimating equation analysis of ≥ 2 repeated measurements of cardiovascular disease markers over 4 years

From: Longitudinal follow-up of health effects among workers handling engineered nanomaterials: a panel study

 

Control

Risk Level 1

Risk Level 2

GEE analysis coefficient B (SE)

Model 1

Model 2

Variablesa

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

RL1*Time

RL2*Time

RL1*Time

IL-6 (pg/mL) 1st

35

9.9 ± 4.04

53

9.27 ± 3.34

45

9.81 ± 4.2

-0.314 (0.285) ★★

-0.759 (0.276)

-0.355 (0.136) ★★

IL-6 (pg/mL) 2nd

74

4.35 ± 3.29

82

5.45 ± 3.83

66

5.54 ± 3.95

IL-6 (pg/mL) 3rd

73

2.79 ± 3.03

73

6.11 ± 11.35

72

3.95 ± 8.53

IL-6 (pg/mL) 4th

79

3.89 ± 7.51

68

3.51 ± 7.77

65

1.71 ± 2.2

IL-6 (pg/mL) 5th

46

3.06 ± 2.29

41

2.49 ± 2.4

44

2.04 ± 1.61

IL-6 sR (ng/mL) 1st

35

37.88 ± 11.76

53

35.64 ± 10.1

46

34.79 ± 10.65

0.523 (0.752)

0.809 (0.700)

0.377 (0.348)

IL-6 sR (ng/mL) 2nd

75

46.45 ± 11.87

82

40.72 ± 11.04

68

41.14 ± 11.87

IL-6 sR (ng/mL) 3rd

73

33.87 ± 13.35

73

32.02 ± 12

72

33.77 ± 12.01

IL-6 sR (ng/mL) 4th

79

31.52 ± 9.91

68

31.63 ± 8.87

65

31.21 ± 9.24

IL-6 sR (ng/mL) 5th

64

48.57 ± 10.07

52

49.68 ± 10.61

57

46.72 ± 10.2

MPO (ng/mL) 1st

33

63.14 ± 28.91

51

77.26 ± 53.71

43

84.61 ± 51.55

-6.446 (4.372)

-6.877 (4.660)

-3.600 (2.305)

MPO (ng/mL) 2nd

74

90.94 ± 36.38

81

106.97 ± 56.87

66

117.94 ± 70.02

MPO (ng/mL) 3rd

73

88.83 ± 47.01

74

105.16 ± 44.11

71

96.79 ± 43

MPO (ng/mL) 4th

79

171.54 ± 80.19

68

166.01 ± 79.85

65

184.4 ± 94.49

MPO (ng/mL) 5th

63

164.63 ± 96.94

51

186.14 ± 128.59

57

156.37 ± 102.1

Arylesterase 1st

34

128.67 ± 29.24

51

128.32 ± 24.02

44

124.5 ± 25.05

-4.563 (1.741) ★★

-2869 (1.597)

-1.531 (0.789)

Arylesterase 2nd

74

87.33 ± 29.67

82

99.2 ± 30.37

67

96.48 ± 28.3

Arylesterase 3rd

73

83.38 ± 13.19

74

80.23 ± 12.03

72

81.22 ± 12.16

Arylesterase 5th

64

91.88 ± 15.35

52

95.51 ± 20.73

57

90.2 ± 16.5

  1. a.times of measurements (1st: at baseline; 2nd: at 6 months later; 3rd: at 18 months later; 4th: at 30 months later; 5th: at 42 months later)
  2. ★★ p-values interaction term <0.01 in the GEE model
  3. Analytical Model (Dependent variable: IL-6) includes main effects of sex, and smoking.
  4. Analytical Model (Dependent variable: IL-6 sR) includes main effects of age, sex, and smoking.
  5. Analytical Model (Dependent variable: MPO) includes main effects of age, sex, smoking, drinking, arrhythmia, and hypertension.
  6. Analytical Model (Dependent variable: Arylesterase) includes main effects of sex, and smoking.
Back to article page

Environmental Health

ISSN: 1476-069X